Guizhou University of Traditional Chinese Medicine, Guiyang, 550002, China.
First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, 550001, China.
Trials. 2022 May 28;23(1):446. doi: 10.1186/s13063-022-06382-x.
Lumbar disc herniation (LDH) is a common and frequently occurring disease in clinics. Low back pain and sciatica are the presenting symptoms of LDH. To some extent, it can be considered that measures with the capability to improve low back pain or sciatica have the potential to treat LDH. Ma's bamboo-based medicinal moxibustion therapy can effectively reduce the degree of low back pain and has been widely used. Studies of small sample size have seen significant improvement on pain relief. The aim of this trial is to evaluate the clinical efficacy and safety of Ma's bamboo-based medicinal moxibustion therapy in the treatment of LDH low back pain.
METHODS/DESIGN: The trial is a multicenter, randomized, parallel-group, non-inferiority study. Three hundred and twelve patients will be randomly assigned to a Ma's bamboo-based medicinal moxibustion group (n=156) and an acupuncture group (n=156). Patients in each group will receive treatment every day, 6 times a week, 12 times in total. Follow-up will be conducted 14 days after treatment. The primary outcome will be the visual analog scale(VAS) at baseline, after 6 times of treatment, end of treatment, and follow-up. The secondary outcomes will include Oswestry disability indexes (ODI), modified Japanese Orthopaedic Association low back pain (M-JOA) score, serum β-endorphin (β-EP), and serum substance P (SP). β-EP and SP, as well as safety evaluation indexes (routine blood, liver, and kidney function and electrocardiogram), will be measure at baseline and after the end of treatment. The number, nature, and severity of adverse events will be recorded.
The results of the trial will compare the efficacy of low back pain in LDH between Ma's bamboo-based medicinal moxibustion group and the acupuncture group and will be expected to make a systematic and objective evaluation of the clinical efficacy and safety of Ma's bamboo-based medicinal moxibustion therapy.
ChiCTR2000038725 . Registered on 29 September 2020.
腰椎间盘突出症(LDH)是临床常见多发病,腰痛伴下肢放射痛是其主要临床表现,在某种程度上可以认为能改善腰痛或下肢放射痛的措施均有可能治疗 LDH。麻氏竹药灸疗法能有效缓解腰痛程度,已广泛应用于临床。小样本量的研究显示其在缓解疼痛方面有显著改善。本试验旨在评价麻氏竹药灸治疗 LDH 腰痛的临床疗效和安全性。
方法/设计:本试验为多中心、随机、平行分组、非劣效性研究。将 312 例患者随机分为麻氏竹药灸组(n=156)和针刺组(n=156)。两组患者均每日治疗 1 次,每周 6 次,共治疗 12 次。治疗结束后 14 天进行随访。主要结局指标为治疗前、治疗 6 次后、治疗结束时、随访时的视觉模拟评分(VAS)。次要结局指标包括 Oswestry 功能障碍指数(ODI)、改良日本骨科协会腰痛评分(M-JOA)、血清β-内啡肽(β-EP)、血清 P 物质(SP)。治疗前后分别检测β-EP、SP 及血常规、肝肾功能、心电图等安全性评价指标。记录不良事件的发生例数、性质和严重程度。
本试验将比较麻氏竹药灸组和针刺组治疗 LDH 腰痛的疗效,有望对麻氏竹药灸疗法的临床疗效和安全性做出系统、客观的评价。
ChiCTR2000038725,于 2020 年 9 月 29 日注册。